Publications
10 results found
Black J, Atkinson S, Singh A, et al., 2019, The inflammation-based index can predict response and improve patient selection in NETs treated with PRRT: a pilot study, Journal of Clinical Endocrinology and Metabolism, Vol: 104, Pages: 285-292, ISSN: 0021-972X
BackgroundPeptide Receptor Radionuclide Therapy (PRRT) is an effective treatment for certain patients with metastatic neuroendocrine tumours (NETs). Tumour response is highly variable; no biomarker in clinical practice has been demonstrated to reliably predict outcome. The Inflammation-Based Index (IBI), derived from serum C-reactive protein and albumin levels, predicts survival and response to treatment in patients in a number of cancer types and was therefore explored in this setting.Materials and MethodsClinico-pathological data from patients undergoing PRRT for metastatic NETs were collected at baseline and during treatment. The primary endpoint was progression free survival (PFS) with a secondary endpoint of overall survival (OS). Cox regression analysis tested associations between baseline variables and their dynamic changes, and PFS and OS. Decision curve analysis (DCA) was used to determine the net benefit associated with a treatment strategy determined by the baseline IBI and non-response to PRRT.ResultsFifty-five patients were recruited. Baseline IBI >0 was associated with inferior PFS (HR 14.2 (95% CI 5.25-38.5), p<0.001) and OS (p<0.001). Multivariate analysis confirmed an independent association between IBI and PFS (p=0.001). DCA indicated a net clinical benefit at risk thresholds between 0.03 and 0.58.ConclusionBaseline IBI score and its dynamic change through treatment are associated with both PFS and OS. At a risk threshold equivalent to the currently accepted rate of non-response to therapy, implementation of this easily derived score could avoid a significant number of futile treatments. These findings should be validated in additional independent cohorts.
Evans J, Kitson R, Shah R, et al., 2018, 30-day mortality following initiation of immunotherapy for advanced stage lung cancer, 16th Annual Meeting of the British Thoracic Oncology Group, Publisher: Elsevier, ISSN: 0169-5002
Sharma R, Wang WM, Evans J, et al., 2017, 68Ga-DOTATATE PET/CT to predict response to peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumours (NETs), ASCO, Publisher: American Society of Clinical Oncology, ISSN: 0732-183X
Yen C, Sharma R, Rimassa L, et al., 2017, Treatment-stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational study, International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Publisher: ELSEVIER SCIENCE BV, Pages: S223-S224, ISSN: 0168-8278
Khan SA, McClements S, Reccia I, et al., 2016, The next generation of hepatocellular cancer experts: what do they think?, Hepat Oncol, Vol: 3, Pages: 213-215
Dalla Pria A, Bendle M, Ramaswami R, et al., 2015, The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy, Cancer Chemotherapy and Pharmacology, Vol: 77, Pages: 653-657, ISSN: 1432-0843
Brockbank EC, Evans J, Singh N, et al., 2012, Ovarian recurrence from a Stage 1b1 cervical adenocarcinoma previously treated with radical vaginal trachelectomy: A case report., Gynecol Oncol Case Rep, Vol: 2, Pages: 51-53, ISSN: 2211-338X
► Post cervical cancer treatment new pelvic abnormality must be regarded as recurrence. ► Benign MRI features does not exclude recurrence from previous cervical adenocarcinoma.
Brown N, Evans J, 2009, Applying to the foundation programme 2010, BMJ, Pages: b3832-b3832, ISSN: 0959-8138
Evans JS, Turner MD, 2007, Emerging functions of the calpain superfamily of cysteine proteases in neuroendocrine secretory pathways, JOURNAL OF NEUROCHEMISTRY, Vol: 103, Pages: 849-859, ISSN: 0022-3042
- Author Web Link
- Cite
- Citations: 28
Prudden J, Evans JS, Hussey SP, et al., 2003, Pathway utilization in response to a site-specific DNA double-strand break in fission yeast, EMBO JOURNAL, Vol: 22, Pages: 1419-1430, ISSN: 0261-4189
- Author Web Link
- Cite
- Citations: 48
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.